1. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group;Sanz;Blood,1999
2. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients;Niu;Blood,1999
3. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia;Zhu;N. Engl. J. Med.,2014
4. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups;Sanz;Blood,2000
5. Integration of genomic and transcriptomic markers improves the prognosis prediction of acute promyelocytic leukemia;Lin;Clin. Cancer Res.,2021